GlobeNewswire by notified

Scanfil plc’s annual report for 2021 has been published

Share

Scanfil plc     Stock exchange release     25 March 2022 at 8.00 a.m. EET

Scanfil plc’s annual report for 2021 has been published

Scanfil plc has today published its Annual Report for 2021. The Annual Report includes Sustainability Report, Report by the Board of Directors, Financial Statements, Auditor’s Report, Corporate Governance Statement, and Remuneration Report.

The Financial Statements have been published under the European Single Electronic Format (ESEF) reporting requirements as XHTML file. The primary statements have been labelled with XBRL tags. The audit firm KPMG Oy Ab has provided an independent auditor’s reasonable assurance report on Scanfil’s ESEF Financial Statements.

The Annual Report is attached to this release as PDF and XHTML files. Annual Report is also available at www.scanfil.com

Further information:

Pasi Hiedanpää
Director, Investor Relations and External Communications
email: pasi.hiedanpaa@scanfil.com
tel. +358 50 378 2228

Scanfil is an international manufacturing partner and system supplier for the electronics industry with over 45 years of experience in demanding manufacturing. Scanfil provides its customers with an extensive array of services, ranging from product design to product manufacturing, material procurement and logistics solutions. Vertically integrated production and a comprehensive supply chain are the foundation of Scanfil’s competitive advantages: speed, flexibility and reliability.

Typical Scanfil products are modules or integrated products for e.g. self-service application, automation systems, wireless connectivity modules, climate control systems, collection and sorting systems, analyzers and weather solutions. Scanfil services are used by numerous international automation, safety, energy, cleantech, connectivity and health service providers, as well as companies operating in the field of urbanization. Scanfil’s network of factories consists of 9 production units in Europe, Asia and North America. Read more: www.scanfil.com

Attachments

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Zenas BioPharma Submits Investigational New Drug Application in China for ZB001 for the Treatment of Thyroid Eye Disease16.5.2022 00:00:00 CEST | Press release

WALTHAM, Mass. and SHANGHAI, China, May 15, 2022 (GLOBE NEWSWIRE) -- Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies for patients in need around the world, today announced the submission of an investigational new drug (IND) application to the China National Medical Products Administration (NMPA) for the initiation of a Phase 1/2 clinical study of ZB001 for the treatment of Thyroid Eye Disease (TED). This study is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ZB001. “The ZB001 IND submission to the NMPA marks a significant milestone for Zenas,” said Hua Mu, MD, PhD, Chief Executive Officer at Zenas. “There are currently no approved therapies for TED patients in China. Treatment options are limited and often involve high doses of steroids associated with serious side effects or surgical intervention. ZB001 has the potential to change the tre

Cool Company Ltd. – Mandatory Notification of Trade15.5.2022 14:52:24 CEST | Press release

EPS Ventures Ltd., close associate of Cyril Ducau, Chair of the Board of Cool Company Ltd. (the “Company”), has on 13 May 2022 acquired 38,419 shares in the Company at a price of NOK 84.63 per share. Following the transaction, EPS Ventures Ltd. holds a total of 15,038,419 shares in the Company, equivalent to 37.59% of the Company’s shares. Please see attached notification form in accordance with the Market Abuse Regulation article 19. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. Attachment Primary insider notification form

Monthly information related to total number of voting rights and shares composing the share capital – April 30, 202213.5.2022 18:00:00 CEST | Press release

Monthly information related to total number of voting rights and shares composing the share capital –April 30, 2022. Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol : ERYP) Website : www.erytech.com DateTotal of shares composing the share capitalTotal of brut(1) voting rights Total of net (2) voting rights December 31, 202131 018 55332 518 33932 515 839January 31, 202231 018 55332 518 33932 515 839February 28, 202231 018 55332 518 54732 516 047March 31, 202231 018 55332 518 54732 516 047April 30, 202231 018 55332 518 54732 516 047 (1) Gross voting rights number (or « theoretical » voting rights) is used as a basis for calculating the crossing of the threshold. In accordance with article 223-11 of general regulation of Autorité des Marchés Financiers, this number is calculated on t

Hövding ansöker om avnotering från Nasdaq First North Growth Market13.5.2022 17:45:00 CEST | Pressemelding

Styrelsen för Hövding Sverige AB (publ) (”Hövding”) har beslutat att ansöka om avnotering av Hövdings aktie från Nasdaq First North Growth Market (”First North”). Sista dag för handel på First North kommer att meddelas efter att Hövding erhållit bekräftelse om detta från Nasdaq. Fosielund Holding AB (”Fosielund”) offentliggjorde genom pressmeddelande den 13 januari 2022 ett offentligt budpliktserbjudande till aktieägarna i Hövding (”Erbjudandet”). Fosielund meddelande genom pressmeddelande den 16 februari 2022 att Fosielund (med närstående), efter redovisning av likvid i Erbjudandet, innehade 18 021 741 aktier motsvarande ca 65 procent av aktierna och rösterna. Den 8 april 2022 meddelade Fosielund genom pressmeddelande att de förvärvat en större post aktier i Hövding, varefter Fosielund innehade ca 88,7 procent av aktierna och rösterna samt en avsikt att förvärva ytterligare aktier. Den 4 maj 2022 meddelade Fosielund genom pressmeddelande att de förvärvat ytterligare aktier och att des

Fosielund Holding AB påkallar inlösen av återstående aktier i Hövding Sverige AB (publ)13.5.2022 17:45:00 CEST | Pressemelding

Pressmeddelande 13 maj 2022 Ej för offentliggörande, distribution eller publicering, varken direkt eller indirekt, i eller till Storbritannien, USA, Kanada, Japan, Australien, Hong Kong, Nya Zeeland, Schweiz, Sydafrika eller annan jurisdiktion där offentliggörande, distribution eller publicering skulle vara olaglig eller kräva registrering eller annan åtgärd. Fosielund Holding AB påkallar inlösen av återstående aktier i Hövding Sverige AB (publ) Fosielund Holding AB, org.nr 556140-5167, (”Fosielund Holding”) har idag till styrelsen för Hövding Sverige AB (publ), org.nr 556708-0303, (”Hövding”) påkallat inlösen av återstående aktier i Hövding från de övriga aktieägarna, i enlighet med 22 kap. 1 § aktiebolagslagen. Överenskommelse om inlösen av aktierna har inte kunnat träffas med samtliga övriga aktieägare. Fosielund Holding har därför begärt att tvisten avgörs av skiljemän i enlighet med 22 kap. 6 § aktiebolagslagen. För ytterligare information, vänligen kontakta: Joel Eklund, 040-6701